Champions Oncology Inc 2025年度报告

Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 or Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Registrant’s telephone number, including area code:(201) 808-8400 Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act:None. Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive DataFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (orfor such shorter period that the registrant was required to submit and post such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule12b-2 of the Exchange Act. Largeacceleratedfiler Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on the attestation to its management’s effectiveness of its internal controlover financial reporting under section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262 (b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements ofthe registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis ofincentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).YesNo The approximate aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant as of October31, 2025 was $28.6million based on the closing price of the Registrant’s common stock as quoted on the Nasdaq Capital Market as of thatdate. The number of shares of common stock of the Registrant outstanding as of July 23, 2026 was 13,893,569. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive Proxy Statement for its 2026 Annual Meeting of Shareholders to be filed with the Securities andExchange Commission pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, are incorporated by reference intoPart III of this Form 10-K. INDEX TO FORM 10-KFOR THE YEAR ENDED APRIL 30, 2026 PART IItem 1.Business2Item 1A.Risk Factors6Item 1B.Unresolved Staff Comments14Item 1C.Cybersecurity14Item 2.Properties14Item 3.Legal Proceedings14Item 4.Mine Safety Disclosures15PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities15Item 6.Reserved15Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations15Item 7A.Quantitative and Qualitative Disclosures About Market Risk20Item 8.Financial Statements and Supplementary Data20Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure20Item 9A.Controls and Procedures21Item 9B.Other Information21Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections21PART IIIItem 10.Directors, Executive Officers and Corporate Governance22Item 11.Executive Compensation22Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters23Item 13.Certain Relationships and Related Transactions, and Director Independence23Item 14.Principal Ac